Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 25, 2022Clinical and Experimental Dermatology

Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin ( IL )‐17 or IL ‐12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYan XieHunan Normal UniversityYLYang LiuCanterbury Christ Church University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Xie et al. (2022) studied this question.

synapsesocial.com/papers/6a83193ff568d6f39593cb93https://doi.org/10.1111/ced.15237
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease2007 · 152 citations
  2. 2Management of psoriasis as a systemic disease: what is the evidence?2019 · 545 citations
  3. 3Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis2019 · 79 citations
  4. 4Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial2017 · 413 citations